Market news

Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a

Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.

Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.

Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140

Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that […]

Roivant Sciences (NasdaqGS: ROIV) reported positive Phase 2 PHocus trial results for mosliciguat in PH-ILD patients. The study showed statistically significant and clinically meaningful changes in pulmonary vascular resistance and six-minute walk distance measures. Management highlighted the PHocus findings at recent scientific conference presentations focused on pulmonary hypertension and interstitial lung disease. There is more to Roivant than the PHocus mosliciguat data investors are...

Roivant Sciences outlook: LISRAYA approval strengthens revenue, while brepocitinib and mosliciguat could expand immunology/pulmonary franchises. Click for more on ROIV stock.

Roivant Sciences Ltd. (NASDAQ:ROIV) soared to a new all-time high on Tuesday after reporting stellar results from the clinical trial of its treatment candidate for pulmonary hypertension associated with interstitial lung disease (PH-ILD). In intra-day trading, the stock jumped to its highest price of $42.50 before trimming gains to end the session just up by […]

Roivant Sciences (ROIV) jumps 19% to a 52-week high after mosliciguat hit Phase 2 pulmonary hypertension endpoints—get the latest ROIV stock update and key...

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results in lung and swelling diseases.

I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Roivant (ROIV).

Pulmovant, a clinical-stage biotech and Roivant (NASDAQ:ROIV) company, on Tuesday shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD occurs when scarring and inflammation in the lungs restrict blood flow through the pulmonary arteries, raising blood pressure within the lungs. Presented at the European Respiratory Society International Congress 2026, the data highlight meaningful c

These are the stocks posting the largest moves premarket.

PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any randomized controlled PH trialThe study also met its secondary endpoints at Week 16 with a +35.2-meter placebo-adjusted improvement in six-minute walk distance (6MWD, p=0.0027) and a -53.2% (357.7 pg/mL) placebo-adjusted reduction in N-terminal pro–B-ty

Roivant Sciences Ltd. (NASDAQ:ROIV) and Priovant Therapeutics have moved quickly to commercialize Lisraya following its FDA approval for dermatomyositis. The partners launched the daily pill immediately and set a list price of $35,000 for a 30-day supply. The price illustrates the potential value of introducing the first targeted oral treatment for a rare condition with […]

Roivant Sciences Ltd. (NASDAQ:ROIV) and partner Priovant Therapeutics have secured FDA approval for Lisraya, the first oral treatment for dermatomyositis, which is a rare condition that causes painful skin rashes and progressive muscle weakness. The approval gives patients an oral alternative in a disease with limited targeted treatment options. It also creates a new commercial […]